Table adapted from supplement to Lebwohl M, et al. 2015.2 Table S11 and Table S12.
Patient-yr = Total patient years of exposure through week 52 excluding periods of placebo exposure in the induction phase. n, number of adverse events; r, exposure-adjusted event rate per 100 patient-years (n/Patient-yr100);**Three events of suicide attempt occurred in one individual; the first event occurred during the 12 week induction period; †Fatal events in AMAGINE-2 were cardiac arrest (constant 210 mg), cardiac arrest (ustekinumab), pancreatic carcinoma (ustekinumab); one additional fatal event occurred after the exposure period: completed suicide (placebo/210 mg; 27 days after last dose). Fatal events in AMAGINE-3 were cardiac arrest (140 mg/210 mg), accidental death motor vehicle (210 mg/140 mg Q2W); two additional fatal events occurred after the exposure period: histiocytosis haematophagic syndrome (140 mg/140 mg Q4W/210 mg rescue; 41 days after the last dose) and cardiomyopathy (210 mg /140 mg Q4W/210 mg rescue; 87 days after the last dose).
In the brodalumab clinical trials programme, there were 6 suicide attempts, and 4 completed suicides of which 3 were in the brodalumab group (N=4,464). The majority of patients with suicidal behaviour had a history of depression and/or suicidal ideation or behaviour (SIB) and available evidence does not support a causal association between brodalumab and SIB.3
Please consult the SmPC for full details.